Drugs / Candida antigen vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05291845 | Apr 2022 → Oct 2025 overdue | common wart, human papilloma virus infection | Zagazig University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candida antigen vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05291845 ↗ |
| Modality | Vaccine | “Candida antigen vaccine” NCT05291845 ↗ |
| Route | Other | “directly injected with Candida antigen into the largest wart using an insulin syringe” NCT05291845 ↗ |